DiaMedica Therapeutics Upcoming Conference Participation

DMAC Stock  USD 4.62  0.08  1.70%   
About 61% of DiaMedica Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding DiaMedica Therapeutics suggests that many traders are alarmed. The current market sentiment, together with DiaMedica Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use DiaMedica Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 for th

Read at businesswire.com
businesswire News
  

DiaMedica Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards DiaMedica Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

DiaMedica Therapeutics Fundamental Analysis

We analyze DiaMedica Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

DiaMedica Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

DiaMedica Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DiaMedica Therapeutics stock to make a market-neutral strategy. Peer analysis of DiaMedica Therapeutics could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics with similar companies.

Peers

DiaMedica Therapeutics Related Equities

MCRBSeres Therapeutics   15.58   
0%
100.0%
IOVAIovance Biotherapeutics   8.42   
0%
54.0%
HOOKHookipa Pharma   6.51   
0%
41.0%
LYRALyra Therapeutics   5.56   
0%
35.0%
SCPHScpharmaceuticals   1.79   
0%
11.0%
TERNTerns Pharmaceuticals   1.40   
0%
8.0%
IKTInhibikase Therapeutics   1.30   
0%
8.0%
MISTMilestone Pharmaceuticals   0.54   
0%
3.0%
CNTACentessa Pharmaceuticals   0.35   
0%
2.0%
ONCYOncolytics Biotech   1.05   
6.0%
0%
DAWNDay One   2.19   
14.0%
0%
XFORX4 Pharmaceuticals   8.11   
52.0%
0%

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Valuation
Check real value of public entities based on technical and fundamental data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets